Embed Size (px)
Citation preview
Hale & Tempest
India UKIBC Briefing
Dr. Brian W Tempest
www.briantempest.com
UK India Business Council
Manchester 10 March 2011
Hale & Tempest
Dr Brian Tempest advises Companies, Banks, High Net Worth Individuals and Investment Funds on their Strategy in the Emerging World based on his wide experience in China, Japan, South East Asia
and India where he has lived for the last decade.Brian has worked for Ranbaxy Laboratories since 1995 holding the position of Managing Director and Chief Executive Officer until 2005. He was then Chief Mentor and Non Executive Director until 2008. He is one of the few westerners to have led a Sensex Nifty 50 Indian blue Chip MNC and as a result has a valuable insight into India. Brian has also been Regional Director, Far East for Glaxo where he
was responsible for businesses in Japan, China, Korea, and Taiwan.Brian has worked in the Pharmaceutical Industry for the last 39 years and led Healthcare businesses in North America, South America, Europe, Africa, Middle East, Asia and India. He has also led sessions at Investor Meetings across Asia, Europe and USA. He is now an International Advisor to MAPE – India, Religare -India and UNCTAD - Switzerland. In addition he is a member of the SCRIP Global awards panel. Brian speaks at global conferences on the Challenge from India and China and more
information on these presentations can be found on his website www.briantempest.com.Brian has a PhD in Polymer Chemistry from Lancaster University and is a member of the Royal
Society of Medicine, the Royal Society of Chemistry and is a Chartered Chemist. He is now Chairman of Hale & Tempest Co Ltd.
Hale & Tempest
President, CEO, Non Exec Indian Pharma Company - Ranbaxy 1995-2008
One of the few westerners to have a lead a Sensex 50 blue chip Indian MNC
Resided in India 2000-2010, bought & sold homes in Delhi, today an Indian pensioner and Indian tax payer
Non Exec Chairman, Indian Investment Bank, Religare Capital Markets
Non Exec Director, Indian Diagnostic Company, SRL
Non Exec Director, Indian Healthcare Company
Fortis Global Healthcare
India Briefing
Hale & Tempest
The View from Davos
Source – FT
Hale & Tempest
The Indian Education Advantage
Hale & Tempest
The Indian Education Advantage
Engineers/Science graduates pa– India 0.7m, China 0.5m, EU 0.5m, USA 0.4m, Japan 0.3m
Hale & Tempest
Indian Businesses are GlobalPharma Exports by Country
Hale & Tempest
Indian Pharma Sales by Geography Source Ranbaxy 2006
Europe & CIS25%
API8%
Americas33%
Asia27%
Africa7%
$ 1.34b
Hale & Tempest
India Pharma Market Projections Source IPA
Hale & Tempest
FDA Approved Manufacturing Sites
source FDA
Hale & Tempest
USA DMFs ex India
Hale & Tempest
USA DMFs ex China Source FDA
Hale & Tempest
India represents 50% of USA ANDAs
Hale & Tempest
Top Generics Companies Source Generics Bulletin June 2009
Hale & Tempest
Middle Size Generics Companies Source Generics Bulletin June 2009
Hale & Tempest
WHO Pre Qualified Products
Hale & Tempest
Discovery Services in India
Hale & Tempest
Early discovery leads from USA, Europe or Singapore Molecular optimisation from India
Toxicology from China, Central Europe, Singapore Electronic Data Capture India
API Manufacture India
Drug Formulation Manufacture India, USA
Phase 1 Clinical Trials Europe
Phase 2,3 heavy use of India
Corporate back office India
India and Global Drug Development
Hale & Tempest
India R&D Investment
